Projected impact of Cervarix® vaccination on oncogenic human papillomavirus infection and cervical cancer in the United Kingdom.

about

Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy.Association of interleukin-12 gene polymorphisms with cancer susceptibility: a meta-analysis.

P2860

Q33892348-7F398A6F-E44D-44F6-8942-878E90803CF7 Q35791931-98499B4E-525B-4171-B25B-09667E6067A5

P2860

Projected impact of Cervarix® vaccination on oncogenic human papillomavirus infection and cervical cancer in the United Kingdom.

Item

http://www.wikidata.org/entity/Q41648405

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Projected impact of Cervarix® ...... cancer in the United Kingdom.

@en

type

Item

label

Projected impact of Cervarix® ...... cancer in the United Kingdom.

@en

prefLabel

Projected impact of Cervarix® ...... cancer in the United Kingdom.

@en

P1476

Projected impact of Cervarix® ...... cancer in the United Kingdom.

@en

P2093

Cosmina Hogea

http://www.w3.org/2001/XMLSchema#string

Sylvia Taylor

http://www.w3.org/2001/XMLSchema#string

Thierry Van Effelterre

http://www.w3.org/2001/XMLSchema#string

P2860

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

Estimating progression rates for human papillomavirus infection from epidemiological data.

Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model

Estimates of cancer incidence and mortality in Europe in 2008.

Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections.

The cervical cancer epidemic that screening has prevented in the UK.

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.

Cost-effectiveness analyses of human papillomavirus vaccination.

Modeling cervical cancer prevention in developed countries.

Model for assessing human papillomavirus vaccination strategies.

P304

1794

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/HV.28834

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

268876184

http://www.w3.org/2001/XMLSchema#string

P698

25424784

http://www.w3.org/2001/XMLSchema#string

P932

5390500

http://www.w3.org/2001/XMLSchema#string

Projected impact of Cervarix® vaccination on oncogenic human papillomavirus infection and cervical cancer in the United Kingdom.

about

P2860

P2860

Projected impact of Cervarix® vaccination on oncogenic human papillomavirus infection and cervical cancer in the United Kingdom.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932